Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients With Esophageal Adenocarcinoma

Restricted access

Current algorithms for surveillance of patients with esophageal adenocarcinoma (EAC) after chemoradiation and surgery (trimodality therapy [TMT]) remain empiric. The authors hypothesized that the frequency, type, and timing of relapses after TMT would be highly associated with surgical pathology stage (SPS), and therefore SPS could be used to individualize the surveillance strategy. Between 2000 and 2010, 518 patients with EAC were identified who underwent TMT at The University of Texas MD Anderson Cancer Center and were frequently surveyed. Frequency, type, and timing of the first relapse (locoregional and/or distant) were tabulated according to SPS. Standard statistical approaches were used. The median follow-up time after esophageal surgery was 55.4 months (range, 1.0-149.2 months). Disease relapse occurred in 215 patients (41.5%). Higher SPS was associated with a higher rate of relapse (0/I vs II/III, P≤.001; 0/I vs II, P=.002; SPS 0/I vs III, P≤.001; and SPS II vs III, P=.005) and with shorter time to relapse (P<.001). Irrespective of the SPS, approximately 95% of all relapses occurred within 36 months of surgery. The 3- and 5-year overall survival rates were shorter for patients with a higher SPS than those with a lower SPS (0/I vs II/III, P≤.001; 0/I vs II, P≤.001; 0/I vs III, P≤.001; and II vs III, P=.014). The compelling data show an excellent association between SPS and frequency/type/timing of relapses after TMT in patients with EAC. Thus, the surveillance strategy can potentially be customized based on SPS. These data can inform a future evidence-based surveillance strategy that can be efficient and cost-effective.

Correspondence: Jaffer A. Ajani, MD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard (FC10.3022), Houston, TX 77030. E-mail: jajani@mdanderson.org
  • 1.

    JemalABrayFCenterMM. Global cancer statistics. CA Cancer J Clin2011;61:6990.

  • 2.

    SiegelRNaishadhamDJemalA. Cancer statistics, 2013. CA Cancer J Clin2013;63:1130.

  • 3.

    PohlHWelchHG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst2005;97:142146.

    • Search Google Scholar
    • Export Citation
  • 4.

    BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst2008;100:11841187.

    • Search Google Scholar
    • Export Citation
  • 5.

    van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:20742084.

    • Search Google Scholar
    • Export Citation
  • 6.

    AjaniJABarthelJSBentremDJ. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw2011;9:830887.

  • 7.

    MeguidRAHookerCMTaylorJT. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?J Thorac Cardiovasc Surg2009;138:13091317.

    • Search Google Scholar
    • Export Citation
  • 8.

    BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659668.

    • Search Google Scholar
    • Export Citation
  • 9.

    TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:10861092.

    • Search Google Scholar
    • Export Citation
  • 10.

    AbateEDeMeesterSRZehetnerJ. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg2010;210:428435.

    • Search Google Scholar
    • Export Citation
  • 11.

    WuTTChirieacLRAbrahamSC. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol2007;31:5864.

    • Search Google Scholar
    • Export Citation
  • 12.

    ChirieacLRSwisherSGAjaniJA. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer2005;103:13471355.

    • Search Google Scholar
    • Export Citation
  • 13.

    RohatgiPSwisherSGCorreaAM. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer2005;104:23652372.

    • Search Google Scholar
    • Export Citation
  • 14.

    RohatgiPRSwisherSGCorreaAM. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer2005;104:13491355.

    • Search Google Scholar
    • Export Citation
  • 15.

    SudoKTaketaTCorreaAM. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol2013;31:43064310.

    • Search Google Scholar
    • Export Citation
  • 16.

    RiceTWBlackstoneEHRuschVW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol2010;17:17211724.

    • Search Google Scholar
    • Export Citation
  • 17.

    BarbourAPJonesMGonenM. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol2008;15:28942902.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 44 44 1
PDF Downloads 6 6 0
EPUB Downloads 0 0 0